Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Clin Oncol. Sep 24, 2021; 12(9): 800-807
Published online Sep 24, 2021. doi: 10.5306/wjco.v12.i9.800
Figure 2
Figure 2 Overall survival of 88 patients with Hodgkin’s lymphoma treated with either MOPP or ABVD (A) and treated either with or without hematopoietic stem cell transplants (B). ABVD: adriamycin bleomycin vinblastine and dacarbazine; HSCT: Hematopoietic stem cell transplant; MOPP: mechlorethamine, Oncovin, procarbazine, and prednisone.

  • Citation: Sánchez-Valledor LF, Habermann TM, Murrieta-Alvarez I, Córdova-Ramírez AC, Rivera-Álvarez M, León-Peña A, Cantero-Fortiz Y, Olivares-Gazca JC, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Long-term results of the treatment of Hodgkin’s lymphoma in a resource-constrained setting: Real-world data from a single center. World J Clin Oncol 2021; 12(9): 800-807
  • URL: https://www.wjgnet.com/2218-4333/full/v12/i9/800.htm
  • DOI: https://dx.doi.org/10.5306/wjco.v12.i9.800